February 26, 2012

Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients

.   .   

BENEFIT is a randomized controlled trial comparing two different doses of belatacept, a costimulatory blocker, to standard therapy with cyclosporine in de novo kidney transplant patients. Earlier results from this study showed a higher acute rejection rate with belatacept. Nonetheless, at three years, renal function was significantly better in belatacept-treated patents.

Related Articles:

Renal Transplantation

Comments are closed.